Indaptus Therapeutics is trading 7.01% up now at $1.15, extending its recent rebound after closing at $1.07 on August 14, 2026.
- No new company-specific announcement or clearly reported catalyst was identified for August 17, 2026.
- The latest major development, released August 13, covered the Decoy20 trial halt, a neurology pivot, strategic alternatives, and reduced losses.
- Available evidence does not establish that update as the direct cause of today’s move.